Big Pharma is having a harder and harder time cashing in on R&D

Thomson Reuters A recent Deloitte report highlighted a disturbing trend in the pharmaceutical industry: It appears that investments made in research and development just aren't delivering the way they used to. In 2010 Deloitte began following the top 12 pharmaceutical companies by R&D (or research and development) spending recorded the previous year. This 12-company cohort has since launched 186 products with estimated total revenue of $1.258 trillion, and it has collectively advanced 306 drug c...